Depletion in LpA-I:A-II particles enhances HDL-mediated endothelial protection in familial LCAT deficiency

Monica Gomaraschi, Alice Ossoli, Samuela Castelnuovo, Sara Simonelli, Chiara Pavanello, Gloria Balzarotti, Marcello Arca, Alessia Di Costanzo, Tiziana Sampietro, Gaetano Vaudo, Damiano Baldassarre, Fabrizio Veglia, Guido Franceschini, and Laura Calabresi

Centro E. Grossi Paoletti, Dipartimento di Scienze Farmacologiche e Biomolecolari and Section of Chemical and Biomolecular Sciences, DeFENS, Università degli Studi di Milano, Milano, Italy; Centro Dislipidemie, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy; Atherosclerosis Center, Department of Internal Medicine and Allied Sciences, Sapienza University of Rome, Rome, Italy; Institute of Clinical Physiology, CNR, Pisa, Italy; Department of Medicine, University of Perugia, Perugia, Italy; and Monzino Cardiologic Institute, IRCCS, Milano, Italy

Abstract  The aim of this study was to evaluate the vasoprotective effects of HDL isolated from carriers of LCAT deficiency, which are characterized by a selective depletion of LpA-I:A-II particles and predominance of preβ migrating HDL. HDLs were isolated from LCAT-deficient carriers and tested in vitro for their capacity to promote NO production and to inhibit vascular cell adhesion molecule-1 (VCAM-1) expression in cultured endothelial cells. HDLs from carriers were more effective than control HDLs in promoting eNOS activation with a gene-dose-dependent effect (P_trend = 0.048). As a consequence, NO production induced by HDL from carriers was significantly higher than that promoted by control HDL (1.63 ± 0.24-fold vs. 1.34 ± 0.07-fold, P = 0.031). HDLs from carriers were also more effective than control HDLs in inhibiting the expression of VCAM-1 (homozygotes, 65.0 ± 8.6%; heterozygotes, 53.1 ± 7.2%; controls, 44.4 ± 4.1%; P_trend = 0.0003). The increased efficiency of carrier HDL was likely due to the depletion in LpA-I:A-II particles. The in vitro findings might explain why carriers of LCAT deficiency showed flow-mediated vasodilation and plasma-soluble cell adhesion molecule concentrations comparable to controls, despite low HDL-cholesterol levels. These results indicate that selective depletion of apoA-II-containing HDL, as observed in carriers of LCAT deficiency, leads to an increased capacity of HDL to stimulate endothelial NO production, suggesting that changes in HDL apolipoprotein composition may be the target of therapeutic interventions designed to improve HDL functionality.—Gomaraschi, M., A. Ossoli, S. Castelnuovo, S. Simonelli, C. Pavanello, G. Balzarotti, M. Arca, A. Di Costanzo, T. Sampietro, G. Vaudo, D. Baldassarre, F. Veglia, G. Franceschini, and L. Calabresi. Depletion in LpA-I:A-II particles enhances HDL-mediated endothelial protection in familial LCAT deficiency. J. Lipid Res. 2017. 58. 994–1001.

Supplementary key words  endothelium • nitric oxide • apolipoprotein A-II • high density lipoprotein • lecithin:cholesterol acyltransferase

LCAT deficiency is a rare disorder of lipoprotein metabolism due to loss-of-function mutations in the human LCAT gene. LCAT deficiency is inherited in an autosomal dominant fashion with respect to the obligate biochemical phenotypes characterized by reduced plasma cholesterol esterification, LCAT activity, HDL-cholesterol (HDL-C) and apoA-I levels, and enhanced unesterified/total cholesterol ratio (1,2). LCAT deficiency leads to the development of two biochemically and clinically distinct syndromes, classical familial LCAT deficiency (FLD) and fish-eye disease (FED). In FLD cases, the lack of LCAT activity is complete, and the enzyme loses its ability to esterify cholesterol in both HDL and LDL particles with severe clinical manifestations that include corneal opacity, anemia, and renal disease (3). In FED cases, the enzyme loses its capacity to esterify cholesterol in HDL, but retains the activity in LDL, thus leading to less severe clinical manifestations, normally limited to corneal opacity (3). The severe deficiency of atheroprotective HDL in carriers of LCAT deficiency should increase their risk of developing coronary heart disease; however, imaging studies evaluating carotid intima-media thickness, a validated surrogate marker for atherosclerotic

Abbreviations:  BA, brachial artery; BAD, brachial artery diameter; FED, fish-eye disease; FLD, familial LCAT deficiency; FMD, flow-mediated vasodilation; HDL-C, HDL-cholesterol; ICAM-1, intracellular adhesion molecule-1; LDL-C, LDL-cholesterol; LpA-I, lipoproteins containing apoA-I; LpA-I:A-II, lipoproteins containing apoA-I and apoA-II; rHDL, reconstituted HDL; S1P, sphingosine-1-phosphate; VCAM-1, vascular cell adhesion molecule-1.

* M. Gomaraschi and A. Ossoli contributed equally to this work.
† To whom correspondence should be addressed.
§§ email: laura.calabresi@unimi.it

This article is available online at http://www.jlr.org

Copyright © 2017 by the American Society for Biochemistry and Molecular Biology, Inc.

This article is available online at http://www.jlr.org
coronary heart disease (4), suggest that LCAT deficiency does not remarkably increase preclinical atherosclerosis (5, 6), or could even be protective for human arteries (7). The mechanism behind this observation may be linked to an effect of LCAT in raising the plasma content of atherogenic LDL cholesteryl esters, or it may be consequent to the accumulation in LCAT-deficient plasma of highly efficient HDL particles. Indeed, we have shown that sera and isolated HDL from carriers of LCAT deficiency have increased capacity to promote cell cholesterol efflux (8), the most relevant function of HDL (9). Besides their role in reverse cholesterol transport, HDLs can contribute to the maintenance of vascular endothelium homeostasis through a variety of effects on vascular tone, inflammation, and endothelial cell integrity (10, 11). In the last years, it has become evident that the vasoprotective effects of HDL are altered in common pathological conditions, such as acute coronary syndrome (12, 13), diabetes (14), and chronic kidney disease (15, 16), as well as in rare genetic HDL disorders (17). The reason for the impaired endothelial protective activity of HDL in such conditions likely resides in structural HDL properties. In the present study, we evaluated the vasoprotective effects of HDLs isolated from carriers of LCAT deficiency, which are characterized by a selective depletion of large LpA-I-A-II particles and predominance of small preβ migrating HDL (1, 2).

MATERIALS AND METHODS

Subjects

Seventy-five carriers of LCAT gene mutations and 32 family controls, all belonging to the Italian LCAT-deficient families (1, 2), volunteered for the study. The carriers’ group was comprised of nine homozygotes and six compound heterozygotes, defined as homozygotes throughout this study, and 60 heterozygotes. The majority of the carriers included in the present study had FLD (10 homozygotes and 48 heterozygotes); the remaining had FED. HDLs for the in vitro studies were isolated from FLD subjects. All subjects were fully informed of the modalities and end points of the study and signed an informed consent, and the procedures were approved by the Institutional Review Board.

Biochemical analyses

Blood samples were collected after an overnight fast. Plasma total cholesterol, HDL-C, triglyceride, and apolipoprotein levels were determined with certified methods by using a Roche Diagnostics c311 autoanalyzer. LDL-cholesterol (LDL-C) was calculated using Friedewald’s formula.

The plasma concentration of HDL particles containing only apoA-I (LpA-I) and of particles containing both apoA-I and apoA-II (LpA-I:A-II) was determined by electrophoresis in agarose gel (Selva Italia). HDL size was analyzed by nondenaturing gradient gel electrophoresis of the d < 1.21 g/ml plasma total lipoprotein fraction, using precast 4–30% gels (18). Serum preβ-HDL content was assessed after separation by 2D electrophoresis followed by immunodetection against human apoA-I and expressed as a percentage of total apoA-I (18).

Plasma levels of the soluble forms of intracellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and E-selectin were measured by commercial ELISA kits (R&D Systems) (19).

HDL purification

HDLs (d = 1.063–1.21 g/ml) were purified by sequential ultracentrifugation from the plasma of six homozygotes carrying four different LCAT mutations (Thr274-Ile, Arg147-Trp, Lys218-Asn, and Leu372-Arg), 10 heterozygotes carrying six different LCAT mutations (Thr274-Ile, Arg147-Trp, Lys218-Asn, delG stop 16, Val309-Met, and del6 Thr13-Met), and 10 family controls. Due to the very low plasma HDL concentrations detected in homozygotes, plasma samples from three carriers were pooled before ultracentrifugation in order to obtain sufficient amounts of HDL to perform the in vitro experiments; two pools of HDL were thus prepared. HDLs were instead purified by individual plasma samples from heterozygotes and controls.

Purified lipoproteins were dialyzed against sterilized saline immediately before use. HDL content of sphingosine-1-phosphate (SIP) was measured by a commercial competitive ELISA assay and expressed as picomoles per milligram of HDL protein (13). The inter-assay coefficient of variation was 10.4%.

Reconstituted HDL preparation

apoA-I and apoA-II were purified from human plasma, as previously described (20). Discoidal reconstituted HDLs (rHDLs) containing apoA-I and POPC (rLpA-I) were prepared by the cholate dialysis technique, as previously described (21). rHDLs containing both apoA-I and apoA-II (rLpA-I:A-II) were obtained by incubating rLpA-I with lipid-free apoA-II (apoA-II/apoA-I = 1.2, w/w), as previously described (20). rHDLs were then isolated by ultracentrifugation (d < 1.21 g/ml) and the presence of apoA-I and apoA-II was verified by SDS-PAGE followed by Coomassie blue R250 staining. The size of the particles was estimated by gradient gel electrophoresis (21) using the Pharmacia Phast system. Phospholipid content of rHDL was determined by an enzymatic method (22), and proteins were measured by the method of Lowry et al. (23).

Studies on endothelial cells

Experiments were performed on primary cultures of human umbilical vein endothelial cells purchased from Clonetics (Lonza), in M199 with 0.75% BSA and 1% FCS. Plasma HDLs were used at the protein concentration of 1.0 mg/ml in all experiments. rLpA-I and rLpA-I:A-II were used at increasing concentrations (0.125–1.0 mg/ml).

The inhibition of VCAM-1 expression induced by TNFα was assessed as previously described (24). Briefly, endothelial cells were incubated overnight with HDL, washed with PBS, and then stimulated with TNFα (10 ng/ml) for 8 h; VCAM-1 concentration in conditioned medium was evaluated by a commercial matched antibody pairs ELISA kit (BioSource) and normalized by the protein concentration of the total cell lysate.

NO production and eNOS expression and activation in endothelial cells were evaluated as previously described (13). Expression of eNOS was evaluated by SDS-PAGE and immunoblotting after overnight incubation with HDL. Membranes were developed against total eNOS (BD Biosciences), stripped, and reprobed with an antibody against β-actin (Sigma-Aldrich Chemie). eNOS activation by phosphorylation was evaluated by SDS-PAGE and immunoblotting after 10 min of incubation with HDL. Membranes were developed against phosphorylated eNOS (Ser1177; Cell Signal Technology), stripped, and reprobed with an antibody against total eNOS. Bands were visualized by enhanced chemiluminescence (GE Healthcare Biosciences) and analyzed with a GS-690 imaging densitometer and Multi-Analyst software (Bio-Rad Laboratories). NO production was evaluated after 30 min incubation with HDL or rHDL by fluorescence using diacetate 4,5-diaminofluorescein (DAF-2 DA, Sigma-Aldrich Chemie).
Fluorescence intensity was detected with a Synergy multi-mode microplate reader equipped with the GEN5 software (BioTek). For each sample, fluorescence was normalized by the protein concentration of the total cell lysate.

**Assessment of flow-mediated vasodilation**

Flow-mediated vasodilation (FMD) was assessed in 15 of the enrolled carriers (five FLD homozygotes, seven FLD heterozygotes, and three FED heterozygotes), as previously described (25). Because of the small number of available nonaffected family members, a group of 35 control subjects matched for gender and age with the carriers was recruited among blood donors attending the Servizio Immunooematologico Trasfusionale of the Niguarda Hospital in Milano. Evaluations were performed at fasting, between 8:30 AM and 10:30 AM to exclude circadian variations, abstaining from physical activity and smoking since midnight. Ultrasonic scans were performed in a quiet temperature-controlled (22 ± 2°C) room by using a B-mode ultrasound device (ESAOTE Technos MP) equipped with a 5.0–10.0 MHz linear array transducer (ESAOTE LA-525), held throughout the scan at the same point of the brachial artery (BA) of the nondominant arm using a stertotactic device. The ultrasonic device was gated to the peak R-wave on ECG and images were collected during the end-diastolic phase of each cardiac cycle and recorded on SVHS videotapes for offline measurements.

Images of the BA were continuously recorded: i) for 1 min at rest; ii) during 5 min of low-flow obtained by inflating a pneumatic tourniquet placed in the forearm to a pressure 30–50 mmHg above the individual systolic blood pressure; and iii) for 3 min after cuff deflation (i.e., during the reactive hyperemic phase). In each patient, the BA diameter (BAD) was measured using dedicated software, which allowed the automatic and continuous detection of the distance between the media-adventitia interfaces of the near and far wall of the vessel. BAD at rest was the average of the 60 BAD values obtained throughout the preischemic phase. BAD max was the highest BAD value in the hyperemic phase. FMD was calculated as the percent change between BAD at rest and BAD max.

**Statistical analysis**

Results are reported as mean ± SD, if not otherwise stated. Variables with non-Gaussian distribution are presented as median and interquartile range. Tests for differences between groups of normally distributed data were performed using ANOVA followed by Tukey’s test. Differences between groups of non-normally distributed data were performed using the Mann–Whitney U test. The correlation between HDL functions and other variables was evaluated using Spearman’s correlation coefficient. Duration, intensity, and pattern of exercise or smoking were comparable for all groups. All analysts were performed by using the SAS statistical package v. 9.2 (SAS Institute Inc., Cary, NC).

### RESULTS

**Plasma lipids and lipoproteins**

Plasma lipid levels in the examined subjects are reported in Table 1. Plasma total cholesterol and HDL-C, apoA-I, apoA-II, and apoB levels were significantly lower and plasma triglyceride levels were significantly increased, in a gene-dose-dependent manner, in carriers of LCAT mutations compared to controls.

HDL$_2$ was undetectable and HDL$_3$ was smaller in homozygotes, while heterozygotes had normally sized HDL particles (Table 1). Plasma LpA-I and LpA-I:A-II concentrations were significantly reduced in carriers compared with controls, but the decrease in the levels of LpA-I:A-II particles was much greater (−72% in homozgyotes and −50% in heterozygotes) than the decrease in the levels of LpA-I (−50% in homozgyotes and −18% in heterozygotes) (Table 1). The plasma content of preβ HDL was significantly higher in carriers than in controls (Table 1).

HDL content of SIP in homozgyotes was comparable to that of controls’ HDL (195.0 ± 55.2 pmol/mg protein vs. 221.2 ± 28.5 pmol/mg protein, respectively), while HDL from heterozygotes showed a slightly higher SIP content (333.8 ± 162.5 pmol/mg protein, $P_{\text{trend}} = 0.49$).

**Ability of HDL to modulate eNOS activity and NO release in endothelial cells**

HDLs isolated from carriers and controls displayed a comparable capacity to increase eNOS protein abundance ($P_{\text{ANOVA}} = 0.115$) (supplemental Fig. S1). However, HDLs

---

**Table 1. Plasma lipid/lipoprotein levels and HDL subpopulations in carriers of LCAT gene mutations**

<table>
<thead>
<tr>
<th>LCAT Genotype</th>
<th>Homozygotes</th>
<th>Heterozygotes</th>
<th>Controls</th>
<th>$P_{\text{trend}}$</th>
<th>$P_{\text{ANOVA}}$</th>
</tr>
</thead>
<tbody>
<tr>
<td>n</td>
<td>15</td>
<td>60</td>
<td>32</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age (years)</td>
<td>44.1 ± 4.9</td>
<td>48.7 ± 2.7</td>
<td>46.6 ± 3.6</td>
<td>0.86</td>
<td>0.73</td>
</tr>
<tr>
<td>Gender (male/female)</td>
<td>14/1</td>
<td>39/21</td>
<td>11/21</td>
<td>&lt;0.0001</td>
<td>0.0003</td>
</tr>
<tr>
<td>Total cholesterol (mg/dl)</td>
<td>159.6 ± 22.9</td>
<td>166.5 ± 5.5</td>
<td>193.0 ± 6.5</td>
<td>0.015</td>
<td>0.03</td>
</tr>
<tr>
<td>LDL-C (mg/dl)</td>
<td>98.5 ± 17.6</td>
<td>97.2 ± 5.0</td>
<td>114.4 ± 5.5</td>
<td>0.21</td>
<td>0.30</td>
</tr>
<tr>
<td>HDL-C (mg/dl)</td>
<td>12.1 ± 2.9</td>
<td>41.9 ± 2.1</td>
<td>59.8 ± 2.3</td>
<td>&lt;0.0001</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Triglycerides (mg/dl)$^a$</td>
<td>180 (114–387)</td>
<td>110.5 (81–154.5)</td>
<td>77.5 (62–112.5)</td>
<td>0.0002</td>
<td>0.0004</td>
</tr>
<tr>
<td>apoA-I (mg/dl)</td>
<td>50.2 ± 5.7</td>
<td>102.1 ± 3.0</td>
<td>136.3 ± 4.6</td>
<td>&lt;0.0001</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>apoA-II (mg/dl)</td>
<td>9.6 ± 1.5</td>
<td>29.0 ± 0.8</td>
<td>33.9 ± 1.3</td>
<td>&lt;0.0001</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>apoB (mg/dl)</td>
<td>67.8 ± 13.0</td>
<td>92.2 ± 3.5</td>
<td>88.6 ± 3.9</td>
<td>0.16</td>
<td>0.03</td>
</tr>
<tr>
<td>LpA-I (mg/dl)</td>
<td>28.0 ± 4.2</td>
<td>46.3 ± 1.7</td>
<td>56.4 ± 2.5</td>
<td>&lt;0.0001</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>LpA-I:A-II (mg/dl)</td>
<td>22.5 ± 4.3</td>
<td>53.8 ± 2.4</td>
<td>79.8 ± 3.8</td>
<td>&lt;0.0001</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Preβ HDL (% of apoA-I)$^b$</td>
<td>40.0 (23.0–49.0)</td>
<td>16.0 (11.8–22.0)</td>
<td>12.8 (10.9–14.1)</td>
<td>&lt;0.0001</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>HDL$_2$ size (nm)</td>
<td>N.D.</td>
<td>11.2 ± 0.1</td>
<td>11.1 ± 0.1</td>
<td>0.15</td>
<td>0.35</td>
</tr>
<tr>
<td>HDL$_3$ size (nm)$^b$</td>
<td>7.4 (7.2–7.7)</td>
<td>9.0 (8.8–9.3)</td>
<td>9.0 (8.8–9.0)</td>
<td>&lt;0.0001</td>
<td>&lt;0.0001</td>
</tr>
</tbody>
</table>

---

Data are expressed as mean ± SEM. N.D., not detectable.

$^a$Adjusted for age, gender, and family, except for age, adjusted for gender and family, and gender, adjusted for age and family.

$^b$Expressed as median and interquartile range.
from LCAT-deficient subjects proved to be more effective than HDLs from controls in promoting eNOS activation by phosphorylation with a gene-dose-dependent effect; when compared with HDLs from controls, eNOS activation induced by HDLs from heterozygous and homozygous carriers was 40.8% and 75.4% higher, respectively ($P_{\text{Trend}} = 0.048$) (Fig. 1). As a consequence, NO production induced by HDLs from heterozygous and homozygous carriers was significantly higher than that promoted by control HDLs, with a gene-dose-dependent effect (Fig. 2). Interestingly, among the HDL-related parameters, only LpA-I:A-II levels were independent predictors of HDL-induced eNOS activation ($\beta = -0.017 \pm 0.006$, $P = 0.007$).

The evaluation of FMD in a small group of carriers of LCAT deficiency, comprised of 5 homozygotes and 10 heterozygotes, in comparison with age-gender matched control subjects indicated that carriers do not show impaired FMD despite the low HDL-C levels (Table 2).

**Ability of HDL to inhibit VCAM-1 expression in endothelial cells**

As it has been shown that the stimulatory effect of HDLs on endothelial NO production is critical for their endothelial anti-inflammatory action (12), we further investigated the in vitro effect of carriers’ HDL on the expression of endothelial adhesion molecules. HDLs isolated from LCAT-deficient subjects were more effective than HDLs from controls in inhibiting the expression of VCAM-1. HDLs from homozygotes reduced VCAM-1 expression by 65.0 ± 8.6%, HDLs from heterozygotes by 53.1 ± 7.2%, and control HDLs by 44.4 ± 4.1% (Fig. 3).

No significant differences in soluble VCAM-1, ICAM-1, and E-selectin plasma levels were detected when values of carriers of two, one, or zero mutant alleles were tested for trend (Fig. 4). Levels of sVCAM-1 showed a marked degree of variability in homozygotes and were significantly higher than those of heterozygotes ($P = 0.017$) and controls ($P = 0.046$); this may be due to the presence of renal disease in 9 out of 15 homozygotes (26), as suggested by a trend for elevated VCAM-1 levels in carriers with renal disease compared with those with no sign of renal disease (943.5 ± 395.7 ng/ml vs. 761.1 ± 394.5 ng/ml, respectively).

**Table 2. FMD in carriers of LCAT gene mutations**

<table>
<thead>
<tr>
<th></th>
<th>Carriers</th>
<th>Controls</th>
<th>$P$</th>
</tr>
</thead>
<tbody>
<tr>
<td>n</td>
<td>15</td>
<td>35</td>
<td>0.97</td>
</tr>
<tr>
<td>Age (years)</td>
<td>43.9 ± 3.0</td>
<td>44.1 ± 1.9</td>
<td>0.95</td>
</tr>
<tr>
<td>Gender (male/female)</td>
<td>8/7</td>
<td>19/16</td>
<td>0.75</td>
</tr>
<tr>
<td>BMI (kg/m$^2$)</td>
<td>23.4 ± 0.8</td>
<td>23.7 ± 0.5</td>
<td>0.005</td>
</tr>
<tr>
<td>Total cholesterol (mg/dl)</td>
<td>160.8 ± 12.0</td>
<td>199.1 ± 6.8</td>
<td>0.67</td>
</tr>
<tr>
<td>LDL-C (mg/dl)</td>
<td>105.2 ± 9.8</td>
<td>124.0 ± 5.3</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>HDL-C (mg/dl)</td>
<td>32.9 ± 5.4</td>
<td>56.1 ± 2.2</td>
<td>0.27</td>
</tr>
<tr>
<td>Triglycerides (mg/dl)</td>
<td>113.1 ± 12.4</td>
<td>95.1 ± 9.2</td>
<td>0.18</td>
</tr>
<tr>
<td>FMD</td>
<td>0.237 ± 0.025</td>
<td>0.304 ± 0.030</td>
<td>0.18</td>
</tr>
</tbody>
</table>

Data are expressed as mean ± SEM.

*Comprising 5 homozygotes and 10 heterozygotes, pooled for statistical analysis.

$P$ adjusted for HDL-C = 0.22.
single population of particles with a diameter of 9.8 nm, containing 140 POPC, one apoA-I, and two apoA-II molecules per particle (supplemental Fig. S2, supplemental Table S1).

When endothelial cells were incubated with rLpA-I particles, the promotion of NO production was higher than that obtained with rLpA-I:A-II particles in the whole range of concentrations tested (Fig. 5A). Accordingly, rLpA-I particles were more effective than rLpA-I:A-II particles in promoting eNOS activation by phosphorylation (supplemental Fig. S3A), while eNOS protein abundance was comparable between cells incubated with rLpA-I or rLpA-I:A-II particles (supplemental Fig. S3B). rLpA-I and rLpA-I:A-II particles were equally effective in reducing VCAM-1 expression in endothelial cells (supplemental Fig. S3C).

In additional experiments, HDLs from heterozygous and homozygous carriers were supplemented with an amount of rLpA-I:A-II to restore the LpA-I/LpA-I:A-II ratio observed in controls (HDL to rLpA-I:A-II weight ratio 3:1). After the addition of rLpA-I:A-II, HDLs from heterozygotes and homozygotes displayed an impaired ability to promote NO production by endothelial cells (Fig. 5B).

**DISCUSSION**

In the present study, we took advantage of the availability of a large group of Italian carriers of LCAT gene mutations (1, 2) and showed that: i) HDLs from carriers of LCAT deficiency had an increased capacity, with a gene-dose-dependent effect, to promote the release of NO and to inhibit the expression of adhesion molecules in cultured endothelial cells, likely due to the reduced content in LpA-I:A-II particles; and ii) carriers had normal FMD and plasma soluble adhesion molecule levels despite the low HDL-C levels.

Over the past two decades a number of studies have shown direct protective effects of HDL on endothelial cells; these effects include the ability of HDL to promote the production of vasoactive molecules, such as NO, and to downregulate CAM expression (10, 11). The various HDL subpopulations are differently efficient in maintaining endothelial cell homeostasis (27) and, in some conditions, HDL can lose its protective properties and even become detrimental (28). Genetic HDL disorders represent a unique tool to understand the relationship between...
HDL quantity and quality and HDL function, because carriers of inherited HDL disorders not only have extremely low or high HDL-C levels, but also have abnormal HDL subclass distributions (29).

HDL particle distribution is largely altered in carriers of LCAT gene mutations, being characterized by a reduced content of large HDL₂ particles, an accumulation of small HDL₃ particles, particularly preβ migrating HDL (1, 50), and a selective depletion of apoA-II-containing particles (31). While the role of apoA-II containing HDL in mediating cell cholesterol efflux has been evaluated in a number of studies (20, 32–35), no data are available on the effect of apoA-II in modulating endothelial protective HDL functions. The best characterized endothelial protective HDL function is the capacity to enhance NO production, due to the ability of HDL to promote eNOS expression and activation (24, 36, 37). This effect requires the binding of apoA-I to SR-BI, which leads to the activation of the PI3K/Akt signaling pathway and the subsequent phosphorylation of eNOS (38, 39). The major role of apoA-I is demonstrated by the ability of anti-apoA-I antibody to block eNOS activation by HDL in cultured endothelial cells (38). On the contrary, anti-apoA-II antibody further enhances eNOS stimulation by HDL (38), and the level of apoA-II in HDL is inversely correlated with HDL binding to SR-BI (40), indicating that apoA-II is not necessary and suggesting that it could even be detrimental. In line with this hypothesis, HDLs from carriers of genetic CETP deficiency are enriched in LpA-I:A-II particles and have reduced capacity to stimulate endothelial NO production (17). In addition, an elevated plasma concentration of LpA-I:A-II particles is an independent predictor of a more severe inflammatory response, and is associated with a reduced capacity of HDL to promote endothelial NO production in patients with acute coronary syndrome (13, 41).

The defective ability of LpA-I:A-II particles in promoting endothelial NO release might be explained by the presence of apoA-II itself or by the different proteins carried by the two HDL subclasses. In the present study, we have shown that synthetic HDLs containing apoA-II in addition to apoA-I are less efficient than particles containing only apoA-I in promoting endothelial NO production, likely due to the conformational changes of apoA-I induced by apoA-II (42).

It is thus clear that apoA-I is not only needed, but its conformation is also relevant in defining apoA-I-containing HDL capacity to protect the endothelium. HDL-associated PON1 has been suggested to have a major impact on endothelial function, and PON1 inactivation in HDL results in decreased eNOS-Ser1177 phosphorylation and consequent attenuated NO production (12). Furthermore, HDL from PON1-deficient mice fails to stimulate endothelial NO production, and the supplementation of HDL isolated from these mice with purified PON1 restores the protective function (12). PON1 is mostly found in HDL particles containing apoA-I, but not apoA-II, and apoA-I appears to be of major importance in determining serum PON1 activity and stability, likely establishing the architecture of the HDL particle that optimally binds PON1 (43). Moreover, apoA-II enrichment of HDLs can displace PON1, thus impairing their antioxidant properties (44). Notably, carriers of LCAT deficiency have normal PON1 activity despite the low HDL-C levels (45), differently from what is observed in other genetic low HDL disorders (45, 46).

The impact on arterial function of increased efficiency of HDL isolated from carriers of LCAT deficiency is difficult to determine. However, it is noteworthy that carriers of LCAT deficiency show normal FMD despite the low/very low HDL-C levels. Therefore, one could speculate that the increased ability of carriers’ HDL in protecting endothelial function might overcome the markedly reduced concentration of HDL in these subjects.

It must be underlined that the majority of carriers included in the present study had FLD and, thus, the results may not apply to FED. Indeed, a previous study examined pulse wave velocity in Dutch carriers of LCAT mutations, who mainly had FED, and found an increased arterial stiffness in carriers (47). Interestingly, FLD subjects have a more pronounced reduction in LpA-I:A-II particles, particularly evident in homozygotes (2).

In conclusion, the present results indicate that the selective depletion of apoA-II-containing HDL, as observed in carriers of LCAT deficiency, leads to an increased capacity of HDL to stimulate endothelial NO production. These results place the attention on the apolipoprotein composition of HDL as a target of therapeutic interventions designed to improve HDL functionality.

Fig. 5. NO production by rLpA-I and rLpA-I:A-II. A: Reconstituted particles containing only apoA-I or apoA-I and apoA-II were tested for their ability to induce NO production in endothelial cells. Data are expressed as fold of increase in treated versus untreated cells, n = 3. *P < 0.05 versus rLpA-I:A-II at the same concentration. B: NO production in endothelial cells incubated with HDLs from heterozygous and homozygous patients before and after supplementation with rLpA-I:A-II. Data are expressed as fold of increase in HDL-treated versus untreated cells; n = 3 for heterozygotes and n = 6 for homozygotes (pooled in two preparations).
REFERENCES


